Xueping Li1, Suling Xue1, Qi Zhan1, Xiaolei Sun1, Ning Chen1, Sidi Li2, Jin Zhao1, Xin Hou1, Xubo Yuan1. 1. Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin 300072, China. 2. College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, Shandong Province, China.
Abstract
The early-stage repair of bone injuries dominated by the inflammatory phase is significant for successful bone healing, and the phenotypic transition of macrophages in the inflammatory phase plays indispensable roles during the bone healing process. The goal of this paper is to design a microRNA delivery nanocarrier for strictly temporal guidance of the polarization of macrophages by the sequential delivery of different microRNAs. The results showed that microRNA nanocarriers, synthesized through free radical polymerization, could be internalized by macrophages with about a cellular uptake efficiency of 80%, and the sequential delivery of microRNA-155 nanocarriers and microRNA-21 nanocarriers proved, for the first time, that it could promote an efficient and timely switch from the M1 to the M2 phenotype along the time point of bone tissue repair. The strategy proposed in this paper holds potential for controlling sequential M1-to-M2 polarization of macrophages, which provides another perspective for the treatment of bone tissue regeneration.
The early-stage repair of bone injuries dominated by the inflammatory phase is significant for successful bone healing, and the phenotypic transition of macrophages in the inflammatory phase plays indispensable roles during the bone healing process. The goal of this paper is to design a microRNA delivery nanocarrier for strictly temporal guidance of the polarization of macrophages by the sequential delivery of different microRNAs. The results showed that microRNA nanocarriers, synthesized through free radical polymerization, could be internalized by macrophages with about a cellular uptake efficiency of 80%, and the sequential delivery of microRNA-155 nanocarriers and microRNA-21 nanocarriers proved, for the first time, that it could promote an efficient and timely switch from the M1 to the M2 phenotype along the time point of bone tissue repair. The strategy proposed in this paper holds potential for controlling sequential M1-to-M2 polarization of macrophages, which provides another perspective for the treatment of bone tissue regeneration.
Bone
healing is a complex process involving inflammation, callus
formation, and remodeling.[1,2] Macrophages play pivotal
and dynamic roles in the inflammatory stage and mediate almost all
phases of bone healing.[3] Macrophages can
be activated into M1 or M2 phenotypes in response to microenvironmental
stimuli.[4−6] Macrophages sequential polarization to M1 and M2
phenotypes have been recognized as the core event in the inflammatory
phase, governing the fate of bone repair.[7]M1 phenotype macrophages play a chemotactic role, participate
in
the recruitment of mesenchymal stem cells, and stimulate angiogenesis,
which dominate in the first 3 days after injury.[8−12] Subsequently, macrophages are transiently transformed
into M2 phenotypes, which have been reported to inhibit inflammation
and promote osteogenic differentiation of mesenchymal stem cells.[13,14] However, if proinflammatory cytokines persist and M1 phenotype macrophages
dominate for more than 4 days, they lead to chronic inflammation,
destroy osteogenesis, cause the synthesis of a mineralized extracellular
matrix, and finally delay bone repair or result in failed bone repair.[15,16] Therefore, the intervention treatment of bone injuries should not
only give full play to the role of M1 phenotype macrophages in promoting
inflammation and triggering subsequent bone healing but also achieve
the timely transformation of M1 phenotype macrophages to M2 phenotypes.[17]At present, it has been reported that
many cytokines can regulate
the phenotypic transformation of macrophages. For example, Spiller
et al. reported a decellularized bone scaffold for sequentially delivering
interferon-γ (IFNγ) and IL-4 to regulate the sequential
transformation of macrophage phenotype from M1 to M2, which promoted
angiogenesis and healing.[6] Jumana et al.
designed a biomimetic calcium phosphate coating for the delivery of
IFNγ followed by simvastatin, resulting in the effective M1-to-M2
phenotype transition of macrophages.[18] Many
reports have proved that timing regulation of macrophage phenotype
switch has emerged as a potential strategy to promote bone tissue
regeneration. Although cytokines have been proved to have a good effect
on the regulation of macrophage phenotypes, their application dose
often exceeds the physiological range, resulting in serious side effects.[19,20]MicroRNAs are widely used in the treatment of various diseases
owing to the advantage of multiple targets, which can avoid the above
shortcomings of cytokines.[21−24] Saleh et al. developed an adhesive hydrogel containing
miR-223-5p-loaded nanoparticles to control macrophage polarization
to M2 for promoting wound healing.[25] Although
a single microRNA molecule has been proved in other diseases that
it can promote tissue repair by regulating macrophage polarization,
the method of promoting any phenotypic polarization without considering
the time node is not suitable for bone tissue.[7,17] Therefore,
complying with the natural process of bone repair, the sequential
delivery of multiple genes to regulate macrophage polarization may
be a forceful strategy to accelerate bone healing, and microRNAs have
been reported to be differentially expressed in the activated macrophages,
such as microRNA-127-3p, miR-181a, and miR-451.[26−29] Among them, microRNA-155 is highly
expressed in M1 macrophages and less expressed in M2 macrophages.[30−32] The precise role of microRNA-21 on polarization of macrophage phenotypes
is controversial,[27,33,34] but our unpublished data have proved that the delivery of microRNA-21
can promote macrophage polarization toward M2 phenotypes. Therefore,
this paper intends to use microRNA-155 and microRNA-21 to sequentially
stimulate macrophages toward M1 and M2 phenotype polarization, which
strictly follows the natural process of bone healing and will be a
new strategy to promote bone repair.An important challenge
of gene therapy is to develop safe and effective
gene vectors because exposed microRNA molecules cannot easily pass
through the negatively charged cell membrane and will be rapidly degraded
by enzymes once they enter the circulatory system.[35−37] In the present
study, we designed a kind of positively charged nanocarrier-loaded
microRNAs to guide the phenotypic transition of macrophages (Scheme ). According to the
physiological process of bone repair, microRNA-155 nanocarriers were
first applied to accelerate the transition of macrophages to M1 phenotypes,
and then microRNA-21 nanocarriers were used to transiently convert
macrophages to M2 phenotypes at the appropriate time point (day 3).
This strategy of sequential delivery and the appropriately selected
microRNAs make sure that the phenotypic transformation of macrophages
strictly follows the physiological process of bone repair, which is
verified through in vitro experiments. The sequential delivery of
two microRNAs conforming to the physiological process of bone tissue
repair provides a new strategy for bone repair.
Scheme 1
Schematic Illustration
of the Sequential Delivery of Different MicroRNAs
for Modulating M1-to-M2 Macrophage Polarization
Materials and Methods
Materials
The microRNA-21 mimic (miR-21),
microRNA-155 mimic (miR-155), and 6-carboxy-fluorescein (FAM)-labeled
microRNAs were synthesized by GenePharma (Shanghai, China). The sense
strand sequence of miR-155 was 5′-UUAAUGCUAAUCGUGAUAGGGGUU-3′.
The sense strand sequence of miR-21 was 5′-UAGCUUAUCAGACUGAUGUUGA-3′.
All of the chemical reagents used in this paper were purchased from
Sigma-Aldrich unless otherwise noted, and all reagents were analytical
grade. Methoxy poly(ethylene glycol)-acrylamide (mPEG-AC, Mw 2000)
was purchased from Huateng Pharma (Hunan, China). Culture medium,
paraformaldehyde, and CCK-8 kit were supplied by Dalian Meilun Biotechnology
Co., Ltd. (Dalian, China). 4′,6-Diamidino-2-phenylindole (DAPI)
was purchased from Beyotime Biotechnology Co., Ltd. (Shanghai, China).
Preparation and Characterization of Nanocarriers
The miR-155 nanocarriers (Ng(miR-155)) and miR-21 nanocarriers
(Ng(miR-21)) were synthesized using the same preparation method. Ng(miR-155)
was taken as an example and a series of characterization techniques
were carried out. Briefly, a neutral monomer (acrylamide), a positively
charged monomer (N-(3-aminopropyl)-methacrylamide),
a hydrophilic monomer (methoxy poly(ethylene glycol)-acrylamide, Mw
2000), and miR-155 were mixed in a ratio of 3500:350:150:1. Then,
an acid-degraded cross-linker (ethylene glycol dimethacrylate) was
added to the system, and the ratio of the monomers/cross-linker was
8:1. Subsequently, the polymerization was initiated by ammonium peroxydisulfate
and N,N,N′,N′-tetramethylethylenediamine. Then, the reaction
was carried out at 4 °C for 2 h, followed by dialysis using a
10 KDa dialysis bag against phosphate-buffered solution (PBS, pH =
7.4) to remove free miRNAs, unreacted monomers, and initiators.The ζ potential and particle size distribution of Ng(miR-155)
were measured by dynamic light scattering (DLS, BI-90Plus, Brookhaven
Instruments Ltd.). Transmission electron microscopy (TEM, Jem-2100
f, JEOL, Japan) was used to observe the morphology of Ng(miR-155),
which was stained with 2% phosphotungstic acid. The migration of miR-155
and Ng(miR-155) bands was observed by agarose gel electrophoresis
containing ethidium bromide. Further, after freeze-drying, an appropriate
amount of Ng(miR-155) was scanned by Fourier transform infrared spectroscopy
(FTIR, JASCO FT/IR-420) for verifying the composition of polymer shells.
The elements of polymer shells and naked miR-155 were analyzed by
X-ray photoelectron spectroscopy (XPS) for proving that miR-155 was
completely wrapped by the polymer shells.
Cell
Viability Assays and Cellular Uptake
Efficiency
RAW264.7 cells were used as a cellular model for
evaluation of macrophage phenotypes and were maintained in 1640 culture
medium containing 10% fetal bovine serum and 1% penicillin-streptomycin
at 37 °C in 5% CO2 and 100% humidity. The cell viability
was evaluated by the CCK-8 kit on day 1.[38] RAW264.7 cells were seeded in 96-well plates at a density of 5 ×
103 per well, and a certain concentration gradient of Ng(miR-155)
was incubated with the cells for 24 h. Then, 10% CCK-8 was added to
each well and reacted for 1 h. The absorbance value of solution at
450 nm wavelength was read out using a microplate reader (BioTek).NIH 3T3 cells were used for evaluation of cytotoxicity. The NIH
3T3 cells were incubated at 37 °C in 5% CO2 and 100%
humidity for 3 days after treatment with PBS or 50 nM Ng(miR-155).
Then, the cells were stained with DAPI and FITC-phalloidin and observed
by confocal laser scanning microscopy (A1R+, Nikon).The endocytosis
efficiency of Ng(miR-155) was quantified by detecting
the intracellular fluorescence intensity.[39] Ng(miR-155) was used in subsequent experiments with a concentration
of 50 nM. RAW264.7 cells were seeded in six-well plates at a density
of 1 × 105 per well for 24 h. After being incubated
with miR-155 or Ng(miR-155) for another 4 h, the RAW264.7 cells were
washed with PBS solution to remove the remaining molecules, followed
by fixing with 4% paraformaldehyde for 10 min. Under dark conditions,
the cytoskeleton and nuclei were labeled with phalloidin and DAPI,
respectively. Finally, it was observed and photographed by confocal
laser scanning microscopy, and the quantitively estimated cellular
endocytosis efficiency was tested by flow cytometric analysis (BD
Biosciences). The cells were collected and fixed, followed by washing
with PBS solution. The percentage of fluorescence-positive RAW264.7
cells and mean fluorescence intensity (MFI) were evaluated. All data
were analyzed using FlowJo software.
Flow
Cytometric Analysis of Macrophage Phenotypes
The RAW264.7
cells were maintained in six-well plates at 1 ×
105 cells per well and treated with PBS, Ng(NC), Ng(miR-155),
or Ng(miR-21) for 24 h. Then, the cells were collected and incubated
with PE-conjugated anti-mouse CCR7 (M1 marker, BioLegend) and APC-conjugated
anti-mouse CD206 (M2 marker, BioLegend) at 37 °C for 1 h under
dark conditions. Then, the cells were washed with PBS three times
to remove excess antibodies, followed by resuspension with 500 μL
of PBS. Finally, the fluorescence intensity of the samples was detected
with a flow cytometer, and the effect of Ng(miR-21) on macrophage
phenotypes was studied in detail in our other articles, but we verified
it again in this paper.
Intracellular Reactive
Oxygen Species Detection
Reactive oxygen species (ROS) could
be produced in large quantities
by M1 phenotype macrophages. 2′,7′-Dichlorodihydrofluorescein
diacetate (DCFH-DA) could be hydrolyzed by esterase to produce fluorescence,
which was used as a probe for detecting intracellular ROS. The RAW264.7
cells were treated with PBS or Ng(miR-155), and cultured with DCFH-DA
(10 × 10–6 M) in PBS (37 °C, 30 min).
Finally, fluorescence images were captured by confocal laser scanning
microscopy.
Immunofluorescence Staining
The ratio
of RAW264.7 cells positive for iNOS (M1 marker) and CD206 (M2 marker)
was evaluated by immunofluorescence staining. After treatment with
PBS, Ng(miR-155), or Ng(miR-21) for 24 h, the cells were fixed with
4% paraformaldehyde for 10 min, treated with 0.1% Triton X-100 for
5 min, and blocked in 1% BSA for 1 h. Subsequently, the cells were
incubated with antibodies overnight at 4 °C, followed by washing
three times. Then, the samples were incubated with secondary antibodies
under dark conditions for 1 h at 37 °C, followed by treatment
with DAPI for 10 min. The images were taken by confocal laser scanning
microscopy. The semiquantitative analysis of fluorescence was evaluated
by ImageJ.
Cytokine Secretion
The cell culture
medium stimulated by the above PBS, Ng(miR-155), or Ng(miR-21) for
24 h was tested by an enzyme-linked immunosorbent assay (ELISA) kit
for detection of the concentration of proinflammatory cytokine TNF-α
and anti-inflammatory cytokine IL-10. The supernatants were centrifuged
to remove cellular debris and measured according to the manufacturer’s
instructions. The experiment was performed in triplicate.For
the sequential stimulation of macrophages, Ng(miR-155) was added to
the culture medium. The culture medium was changed after 24 h followed
by washing three times, and then Ng(miR-21) was added to stimulate
it for 24 h. Subsequently, the secretion of cytokines was tested according
to the above steps. Lipopolysaccharides (LPS) were used as a positive
control group to stimulate the inflammatory conditions. RAW264.7 cells
were pretreated with 100 ng/mL LPS for 24 h, and other steps were
performed according to the above descriptions.
Total
RNA isolation and qPCR analysis
To analyze the gene expression
level of cytokines, a fluorescence
quantitative polymerase chain reaction (qPCR) was used. The total
RNA was isolated using a TRNzol Universal Reagent (Tiangen Biotech
Co., Ltd.) according to the manufacturer’s instructions. cDNA
was synthesized from 2000 ng of samples’ RNA using a FastQuant
RT Kit (Tiangen Biotech Co., Ltd.). Then, a SuperReal PreMix Plus
kit (Tiangen Biotech Co., Ltd.) was used for detection expression
of mRNA by a Real-Time PCR Detection System (Bio-Rad). Each sample
was repeated three times, and the comparative cycle threshold (CT)
method (2–ΔΔCT) was used to calculate
the fold changes of mRNAs (iNOS, iL-6, and iL-10). The cycling parameters
were shown as follows: initial denaturation at 95 °C for 15 min,
40 cycles of denaturation at 95 °C for 10 s, annealing at 60
°C for 20 s, and extension at 72 °C for 20 s. The sequences
of primers were listed as follows: iNOS, forward CAGCTGGGCTGTACAAACCTT
and reverse CATTGGAAGTGAAGCGTTTCG; iL-6, forward AGTTGCCTTCTTGGGACTGA
and reverse TCCACGATTTCCCAGAGAAC; iL-10, forward ACTCTTCACCTGCTCCACTG
and reverse GCTATGCTGCCTGCTCTTAC; GAPDH, forward ATCACTGCCACCCAGAAG
and reverse TCCACGACGGACACATTG. GAPDH was used as a quantitative control
for RNA levels.
Statistical Analysis
All data were
shown as the mean ± standard deviation (SD), and the statistical
analyses were carried out using Prism GraphPad software version 8.
Values of p less than 0.05 were considered statistically
significant.
Results and Discussion
A nanocarrier for high-efficiency transfection of macrophages was
designed for the delivery of microRNAs. The nanocarriers were synthesized
by free radical polymerization, and the microRNAs were encapsulated
within polymer shells (Figure A). An acid-degraded cross-linker, ethylene glycol dimethacrylate
(EGDMA), was used to synthesize the microRNA-21 nanoparticles. The
cross-linker molecule degraded within the acidic endosomes (pH = 5.4)
followed by the release of microRNAs. Here, microRNA-155 was loaded
in the nanocarrier for verifying the successful preparation of microRNA
nanocarriers. The results of DLS showed that the particle size of
Ng(miR-155) was evenly distributed at 30–40 nm (Figure B). The sphere-like structure
of Ng(miR-155) could be more intuitively observed from the TEM images
(Figure C). Figure D shows that microRNA-155
was negatively charged, and the ζ potential was about −4.57
mV. The Ng(miR-155) was positively charged due to the amino groups
on the surface of nanocarriers, and the ζ potential was about
7.01 mV. Under the electric field, microRNA-155 migrated from the
negative electrode to the positive electrode, and Ng(miR-155) remained
in the pores (Figure E).
Figure 1
Characterization of microRNA nanocarriers. (A) Schematic illustration
of the synthesis of microRNA nanocarriers. (I) Enriching of the monomers
and cross-linkers around microRNA molecules. (II) Formation of Ng(miR-155)
by free radical polymerization. (III) Release of microRNA-155 from
the nanocarrier upon degradation of the polymer shell. MicroRNA-155
was taken as an example. (B) Particle size distribution of nanocarriers
by DLS. (C) TEM images of nanocarriers. (D) ζ potential of miRNA-155
and Ng(miR-155). (E) Agarose gel electrophoresis. Native miR-155 served
as the control.
Characterization of microRNA nanocarriers. (A) Schematic illustration
of the synthesis of microRNA nanocarriers. (I) Enriching of the monomers
and cross-linkers around microRNA molecules. (II) Formation of Ng(miR-155)
by free radical polymerization. (III) Release of microRNA-155 from
the nanocarrier upon degradation of the polymer shell. MicroRNA-155
was taken as an example. (B) Particle size distribution of nanocarriers
by DLS. (C) TEM images of nanocarriers. (D) ζ potential of miRNA-155
and Ng(miR-155). (E) Agarose gel electrophoresis. Native miR-155 served
as the control.In addition, the characteristic
groups of the polymer shell (1524
and 1493 cm–1, C=O; 943 cm–1, C–N) could also be seen from the FTIR spectrum, indicating
that the microRNAs had indeed been successfully encapsulated in the
nanocarriers (Figure A). XPS showed that the content of the P element decreased greatly
in Ng(miR-155), which further indicated that the microRNAs were encapsulated
inside the nanocarriers (Figure B). Therefore, the microRNA-loaded nanocarriers were
successfully prepared with a weak positive charge and uniform small
size.
Figure 2
(A) FTIR spectrum of Ng(miR-155). (B) XPS images of miRNA-155 and
Ng(miR-155).
(A) FTIR spectrum of Ng(miR-155). (B) XPS images of miRNA-155 and
Ng(miR-155).After that, the macrophage cell
viability was verified by the CCK-8
kit. As shown in Figure A, after incubation with nanocarriers with all concentration gradients
for 24 h, the cell viability of macrophages reached 85%. The effective
concentration used in subsequent experiments in this study was 50
nM, and the cell viability was about 90%. Figure B shows that there was no difference in the
NIH 3T3 cell morphology in control and Ng(miR-155) groups. The results
indicated that Ng(miR-155) had perfect biocompatibility. After incubation
with macrophages for 4 h, the uptake of Ng(miR-155) by macrophages
was analyzed by flow cytometry (Figure C). The results showed that the curve of the Ng(miR-155)
group significantly moved to the right compared with the free miRNA-155
group. The mean fluorescence intensity of cells treated with Ng(miR-155)
was much higher than that of free miRNA-155. The results were further
confirmed by confocal laser scanning microscopy images, which are
shown in Figure D.
There was almost no fluorescence in the free miRNA-155 group, indicating
the poor uptake efficiency by macrophages. In contrast, Ng(miR-155)
was concentrated around the cell nucleus and located in the cell cytoplasm.
Therefore, the results intuitively showed the nanocarriers could be
uptaken by macrophages with high endocytosis efficiency.
Figure 3
(A) RAW264.7
cell viability in different concentration gradients
of Ng(miR-155). (B) NIH 3T3 cell morphology after being treated by
Ng(miR-155). Cells were counterstained with DAPI (nuclei) and FITC-labeled
phalloidin (actin). (C) Flow cytometric analyses of RAW264.7 cells
after incubation with free miR-155 or Ng(miR-155). Quantitative analyses
of fluorescence were shown by mean fluorescence intensity. (D) Confocal
laser scanning microscopy images of the RAW264.7 cells incubated with
free miR-155 and Ng(miR-155). Cells were counterstained with DAPI
(nuclei) and TRITC-labeled phalloidin (actin). Scale bars are 50 μm.
***P < 0.001, ns means no significant difference.
(A) RAW264.7
cell viability in different concentration gradients
of Ng(miR-155). (B) NIH 3T3 cell morphology after being treated by
Ng(miR-155). Cells were counterstained with DAPI (nuclei) and FITC-labeled
phalloidin (actin). (C) Flow cytometric analyses of RAW264.7 cells
after incubation with free miR-155 or Ng(miR-155). Quantitative analyses
of fluorescence were shown by mean fluorescence intensity. (D) Confocal
laser scanning microscopy images of the RAW264.7 cells incubated with
free miR-155 and Ng(miR-155). Cells were counterstained with DAPI
(nuclei) and TRITC-labeled phalloidin (actin). Scale bars are 50 μm.
***P < 0.001, ns means no significant difference.Although microRNA-based therapy has been applied
to various diseases,
there are few studies on the modulation of macrophage polarization
by microRNAs, probably because the application of microRNAs is hindered
by a lack of effective delivery systems for macrophages that are more
difficult to transfect than general cell types.[36] Compared with traditional transfection methods, such as
electroporation, lipofectamine reagent, and plasmid,[40,41] the nanocarriers reported in this paper have the advantages of low
toxicity and high transfection efficiency. To the best of our knowledge,
nanoparticles are seldom reported to deliver microRNAs to macrophages,
and nanoparticles that can efficiently transfect other cells are not
necessarily suitable for macrophages. We previously reported a nanoparticle
that could be uptaken into mesenchymal stem cells,[24] which was also based on free radical polymerization, and
the physicochemical properties of nanoparticles such as particle size
and electrical properties could be regulated by the ratio and type
of monomers, which might be suitable for different kinds of cells.
The transfection effect targeting macrophages was verified for the
first time in this article. Therefore, the above results showed that
the nanocarriers reported in this paper provided a feasible delivery
system for gene therapy targeting macrophages.The results had
shown that the designed nanocarriers could effectively
deliver microRNAs into macrophages. Subsequently, we further studied
the polarization of macrophages by Ng(miR-155). After incubation with
Ng(miR-155) for 24 h, the expressions of CCR7 (M1 marker) and CD206
(M2 marker) of macrophages were detected by flow cytometry. Figure A shows the expression
of the M1 marker, which indicated that after stimulation with Ng(miR-155),
the curve significantly moved to the right (positive results). In
addition, quantitative analysis showed that the positive percentage
of the Ng(miR-155) group was about 31%, which was much higher than
the control group (Figure C). To exclude the effect of the polymer shell on macrophage
polarization, a disordered microRNA sequence (negative control for
microRNA mimics) was used to synthesize NC nanocarriers. Figure S1 shows that the polymer shell did not
affect the polarization of macrophages to M1 phenotypes. Therefore,
Ng(miR-155) could promote the transformation of macrophages to M1
phenotypes owing to microRNA-155 molecules rather than the polymer
shell. The trend of mean fluorescence intensity was consistent with
the above results. Figure B,D shows the expression of the M2 marker, which indicated
that irrespective of the qualitative curve or quantitative analysis,
there was no significant difference between the control and Ng(miR-155)
groups. The results of flow cytometry showed that microRNA-155 nanocarriers
could promote the expression of the M1-related marker in macrophages
and had no interference with the M2-related marker.
Figure 4
Flow cytometric analyses
of macrophage phenotypes treated with
Ng(miR-155). (A) The M1 macrophage-related marker CCR7. (B) The M2
macrophage-related marker CD206. (C) Quantitative analyses of the
fluorescence of A. (D) Quantitative analyses of the fluorescence of
B. Scale bars are 50 μm. **P < 0.01; ns
indicates that the groups are not significantly different from each
other.
Flow cytometric analyses
of macrophage phenotypes treated with
Ng(miR-155). (A) The M1 macrophage-related marker CCR7. (B) The M2
macrophage-related marker CD206. (C) Quantitative analyses of the
fluorescence of A. (D) Quantitative analyses of the fluorescence of
B. Scale bars are 50 μm. **P < 0.01; ns
indicates that the groups are not significantly different from each
other.Macrophages are highly plastic
with the stimulation of the microenvironment.
The M1 phenotype macrophages present a round shape with a number of
pseudopodia, while the M2 phenotypes are elongated spindle-shaped.
The representative images of RAW264.7 cells are shown in Figure A. The macrophages
were round with the treatment of PBS, while the macrophages treated
with Ng(miR-155) were with a number of pseudopodia, which was consistent
with the morphology of M1 macrophages. In addition, M1 phenotype macrophages
could produce a high concentration of ROS, which acted to regulate
biological processes. The level of ROS was evaluated via DCFH-DA,
an ROS probe. The results showed that Ng(miR-155) exhibited a remarkable
ROS improvement compared with the control group (Figure B). These results confirmed
that microRNA-155 nanocarriers could promote macrophage polarization
toward M1 phenotypes.
Figure 5
(A) Representative cell morphology of RAW264.7 cells.
(B) Detection
of ROS production. Scale bars are 50 μm.
(A) Representative cell morphology of RAW264.7 cells.
(B) Detection
of ROS production. Scale bars are 50 μm.To further study the effect of microRNAs on phenotype transformation
of macrophages, the immunofluorescence staining analysis of iNOS (M1
marker) and CD206 (M2 marker) was carried out. CD68 was used as a
universal marker of macrophages. The images of macrophages treated
by Ng(miR-155) showed that the fluorescence intensity of the iNOS
marker was stronger than that of the control group (Figure A), and the expression of the
CD206 marker did not show a significant difference (Figure C), which indicated that microRNA-155
nanocarriers could promote the transformation of macrophages to M1
phenotypes. This was also confirmed by the results of semiquantitative
analyses (Figure B,D).
The results also showed that after stimulation with Ng(miR-155), the
ratio of M1/M2 was improved significantly, which could accelerate
the process of inflammation. Many research studies had reported that
M1 phenotype macrophages could recruit mesenchymal stem cells to the
injury site and stimulate the initial formation of blood vessels by
the secretion of TNF-α, IFN-γ, and IL-6,[42−44] which showed that microRNA-155 nanocarriers could activate the follow-up
process of bone repair.
Figure 6
Immunofluorescence images of macrophages with
the treatment of
Ng(miR-155). (A) The expression of iNOS (M1 phenotype-related marker).
(B) Quantitative analyses of the fluorescence of iNOS. (C) The expression
of CD206 (M2 phenotype-related marker). (D) Quantitative analyses
of the fluorescence of CD206. The nuclei were counterstained with
DAPI. Scale bars are 100 μm. ***P < 0.001;
ns indicates that the groups are not significantly different from
each other.
Immunofluorescence images of macrophages with
the treatment of
Ng(miR-155). (A) The expression of iNOS (M1 phenotype-related marker).
(B) Quantitative analyses of the fluorescence of iNOS. (C) The expression
of CD206 (M2 phenotype-related marker). (D) Quantitative analyses
of the fluorescence of CD206. The nuclei were counterstained with
DAPI. Scale bars are 100 μm. ***P < 0.001;
ns indicates that the groups are not significantly different from
each other.Macrophages regulate the process
of inflammation by secreting cytokines,
and macrophages with different phenotypes secrete different cytokines.
Therefore, we can further prove the effect of microRNAs on macrophage
polarization through the identification of cytokines. The proinflammatory
cytokine TNF-α and anti-inflammatory cytokine IL-10 were detected
in the supernatant of macrophages stimulated by Ng(miR-155) for 24
h (Figure A). The
results showed that the level of TNF-α increased significantly
in the Ng(miR-155) group, and the concentration increased from about
390 pg/mL to about 590 pg/mL. However, the concentration of anti-inflammatory
cytokine IL-10 did not change significantly, which remained at about
260 pg/mL. Therefore, compared with the untreated control group, microRNA-155
nanocarriers significantly increased the secretion of proinflammatory
cytokines, but had little effect on the expression of anti-inflammatory
cytokines, which further showed that microRNA-155 nanocarriers could
promote the macrophage polarization toward M1 phenotypes, not M2 phenotypes.
Figure 7
(A) ELISA
assay for TNF-α and iL-10 in the supernatant of
RAW264.7 cells treated with Ng(miR-155). (B) Real-time PCR analysis
of relative gene expression of the M1-related iNOS, IL-6, and M2-related
IL-10. C and (D) Secretion of TNF-α and iL-10 after the sequential
delivery of Ng(miR-155) and Ng(miR-21). *P < 0.05,
**P < 0.01, and ***P < 0.001;
ns indicates that the groups are not significantly different from
each other.
(A) ELISA
assay for TNF-α and iL-10 in the supernatant of
RAW264.7 cells treated with Ng(miR-155). (B) Real-time PCR analysis
of relative gene expression of the M1-related iNOS, IL-6, and M2-related
IL-10. C and (D) Secretion of TNF-α and iL-10 after the sequential
delivery of Ng(miR-155) and Ng(miR-21). *P < 0.05,
**P < 0.01, and ***P < 0.001;
ns indicates that the groups are not significantly different from
each other.The above data have proved that
microRNA-155 nanocarriers could
improve the secretion of proinflammatory cytokines. Then, we further
detected the expression of genes related to macrophage phenotype by
RT-qPCR. As shown in Figure B, Ng(miR-155) significantly upregulated the expression of
proinflammatory M1 macrophage-related genes, such as iNOS and IL-6,
but slightly decreased the mRNA expression of anti-inflammatory M2
macrophage-related genes, such as IL-10, with no significant difference
compared with the control group. All of the above data showed that
microRNA-155 nanocarriers could promote macrophage polarization to
M1, which was consistent with ELISA analysis.The above results
showed that microRNA-155 nanocarriers upregulated
the proinflammatory cytokines iNOS, TNF-α, and IL-6 by promoting
the polarization of macrophages toward M1 phenotypes. Our another
unpublished paper had demonstrated that microRNA-21 nanocarriers could
regulate macrophage polarization to M2 phenotypes in vitro and in
vivo. Here, considering the integrity of the paper, the phenotypic
conversion effect of microRNA-21 nanocarriers on macrophages was reverified,
and the relevant data were listed in the Supporting Information, which was consistent with our previous results
(Figures S2–S4). It was proved again
that microRNA-21 nanocarriers could promote macrophage transformation
toward M2 phenotypes. Therefore, the sequential delivery of Ng(miR-155)
and Ng(miR-21) could theoretically achieve M1 and M2 polarization
of macrophage phenotypes in sequence.To demonstrate that the
phenotypes of macrophages can be switched
sequentially, the secretion of TNF-α and iL-10 after the sequential
delivery of Ng(miR-155) and Ng(miR-21) was detected by ELISA (Figure C,D). The results
showed that under the stimulation of Ng(miR-155), the secretion of
TNF-α increased significantly, with or without LPS, which proved
the emergence of M1 phenotypes (Figure C). Subsequently, the intervention of Ng(miR-21) increased
the secretion of IL-10, which demonstrated that macrophages were rapidly
switched to M2 phenotypes. Therefore, the sequential delivery of microRNA-155
and microRNA-21 nanocarriers could regulate the M1-to-M2 macrophage
phenotype switch.There have been some reports on the systems
for promoting sequential
transformation of macrophage phenotypes. For example, Li et al. reported
an IFNγ-loading calcium silicate/β-tricalcium phosphate
scaffold for modulating M1-to-M2 macrophage transformation.[45] However, IFNγ was sequentially released
over 5 days, and the Si ions released from the scaffold reached 20
ppm in the first 3 days. Namely, this might lead to the persistence
of M1 phenotype macrophages and the early emergence of M2 phenotype
macrophages. Currently, it is recognized that the ideal strategy to
promote bone healing is to repair it, complying with the natural healing
process of bone tissue.[46] If macrophages
can be strictly regulated to express M1 phenotypes in the first 3
days of bone injury and then change to M2 phenotypes, it may be more
conducive to bone tissue regeneration. Similar to the above reports,
most of the reported release systems cannot accurately control the
release of drugs,[6,47] which cannot match the phenotypic
conversion of macrophages during the natural healing of bone tissue.
In comparison, the strategy of the sequential delivery of microRNA-155
and microRNA-21 nanocarriers can sequentially achieve M1 and M2 polarization
of macrophage phenotypes at precise time points. Moreover, an enzyme-sensitive
hydrogel system that achieved the accurate release of two cargoes
was designed by us.[48] By comparison, the
method described in this paper can be completed only by injecting
different nanoparticles at time points with a syringe, which greatly
simplifies the operation steps. Therefore, the sequential delivery
of two microRNA nanocarriers conforming to the time points of macrophage
phenotype transformation during the physiological process provides
an alternative strategy for bone repair.
Conclusions
Multiple gene therapy was first proposed to regulate the M1-to-M2
phenotype transition of macrophages according to the physiological
process of bone tissue repair, and the sequential delivery of microRNA-155
and microRNA-21 nanocarriers could sequentially achieve M1 and M2
polarization of macrophage phenotypes. Our findings demonstrated that
the designed nanocarriers could be effectively internalized by macrophages
with about 80% of endocytosis efficiency within 4 h. MicroRNA-155
nanocarriers could instantaneously modulate macrophage polarization
toward M1 phenotypes as well as improve M1 phenotype-related cytokines
secretion. The positive percentage of M1-related markers in the microRNA-155
nanocarrier group reached about 31%. Subsequently, the intervention
of microRNA-21 nanocarriers could rapidly reverse M1 phenotypes to
M2 phenotypes at the appropriate time point. The therapy strategy
of the sequential delivery of multiple gene targeting phenotype sequential
transition of macrophages provides a new perspective for bone regeneration.
Authors: Katharina Schmidt-Bleek; Hanna Schell; Norma Schulz; Paula Hoff; Carsten Perka; Frank Buttgereit; Hans-Dieter Volk; Jasmin Lienau; Georg N Duda Journal: Cell Tissue Res Date: 2011-07-26 Impact factor: 5.249
Authors: Samiksha Wasnik; Charles H Rundle; David J Baylink; Mohammad Safaie Yazdi; Edmundo E Carreon; Yi Xu; Xuezhong Qin; Kin-Hing William Lau; Xiaolei Tang Journal: JCI Insight Date: 2018-09-06
Authors: Jonathan Stefanowski; Annemarie Lang; Ariana Rauch; Linus Aulich; Markus Köhler; Alexander F Fiedler; Frank Buttgereit; Katharina Schmidt-Bleek; Georg N Duda; Timo Gaber; Raluca A Niesner; Anja E Hauser Journal: Front Immunol Date: 2019-11-26 Impact factor: 7.561